Methicillin-resistant staphylococcus aureus guidelines: A myriad of open questions

Clinical Infectious Diseases

Volumn 53, Issue 1, 2011, Pages 97-98

  Cadena, Jose ^a,b,d   Restrepo, Marcos I ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b Department of Medicine   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTEREMIA; BACTERIAL ENDOCARDITIS; CATHETER INFECTION; DIABETES MELLITUS; HUMAN; IMMUNE DEFICIENCY; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OSTEOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOPHLEBITIS;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 79958855420     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir278     Document Type: Letter

References (9)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
2. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
3. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, andclinical impact of methicillin resistance. Medicine 2003; 82:322-32. (Pubitemid 37229467)
4. Price J, Baker G, Heath I, et al. Clinical and microbiological determinants of outcome in Staphylococcus aureus bacteraemia. Int J Microbiol 2010; 2010:654858.
5. Priest DH, Peacock JE Jr. Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes. South Med J 2005; 98:854-62. (Pubitemid 41396080)
6. Jensen AG, Espersen F, Skinhøj P, Frimodt- Møller N. Bacteremic Staphylococcus aureus spondylitis. Arch Intern Med 1998; 158:509-17. (Pubitemid 128681612)
7. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12. (Pubitemid 32173626)
8. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134:1200-7.
9. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospitalacquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.